The tension between regulatory compliance and antitrust exposure in Orange Book patent listings reached a dramatic inflection point this fall. In late October, Teva Pharmaceuticals agreed to pay $35 ...
The Federal Circuit heard oral argument on November 8, 2024, grappling with the issue of what patent claims may properly be listed in the Orange Book. In late 2023, Teva filed a complaint for patent ...
The Federal Trade Commission announced on Wednesday that Teva Pharmaceutical (TEVA), under pressure from the agency, has requested the removal of more than 200 patents improperly listed in the FDA’s ...
SOLANA BEACH, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results